 Lexaria Bioscience Corp NASDAQ: LEXX has announced initial results from human clinical study HYPER-H21-2 evaluating DehydraTECH-processed cannabidiol CBD for potential application against hypertension. Related Content: DehydraTECH Delivered Colchicine Can Potentially Treat COVID-19, Side Effects From mRNA Shots. 